Evidence map›Paper›PMID 33398302›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation.

S A Kemp, D A Collier, R Datir, Iatm Ferreira, S Gayed, A Jahun, M Hosmillo, C Rees-Spear, P Mlcochova, Ines Ushiro Lumb and 25 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 182 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. SARS-CoV-2 and pathological matrix remodeling mediators.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 9 institutions in 4 countries.

S A KempDivision of Infection and Immunity, University College London, London, UK.
D A CollierDivision of Infection and Immunity, University College London, London, UK.
R DatirDivision of Infection and Immunity, University College London, London, UK.
Iatm FerreiraCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
S GayedDepartment of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
A JahunDepartment of Pathology, University of Cambridge, Cambridge.
M HosmilloDepartment of Pathology, University of Cambridge, Cambridge.
C Rees-SpearDivision of Infection and Immunity, University College London, London, UK.
P MlcochovaCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Ines Ushiro LumbNHS Blood and Transplant, Oxford and BRC Haematology Theme, University of Oxford, UK.
David J RobertsNHS Blood and Transplant, Oxford and BRC Haematology Theme, University of Oxford, UK.
Anita ChandraCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
N TempertonViral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK.
CITIID-NIHR BioResource COVID-19 Collaboration
COVID-19 Genomics UK (COG-UK) Consortium
K SharrocksDepartment of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
E BlaneDepartment of Medicine, University of Cambridge, Cambridge, UK.
Jag BriggsMedical Research Council Laboratory of Molecular Biology, Cambridge, UK.
Gils Mj vanDepartment of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.
Kgc SmithCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
J R BradleyDepartment of Medicine, University of Cambridge, Cambridge, UK.
C SmithDepartment of Virology, Cambridge University NHS Hospitals Foundation Trust.
R DoffingerDepartment of Clinical Biochemistry and Immunology, Addenbrookes Hospital.
L Ceron-GutierrezDepartment of Clinical Biochemistry and Immunology, Addenbrookes Hospital.
G Barcenas-MoralesDepartment of Clinical Biochemistry and Immunology, Addenbrookes Hospital.
D D PollockBiochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, USA.
R A GoldsteinDivision of Infection and Immunity, University College London, London, UK.
A SmielewskaDepartment of Pathology, University of Cambridge, Cambridge.
J P SkittrallDepartment of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
T GouliourisDepartment of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
I G GoodfellowDepartment of Pathology, University of Cambridge, Cambridge.
E Gkrania-KlotsasDepartment of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
Cjr IllingworthDepartment of Applied Mathematics and Theoretical Physics, University of Cambridge, UK.
L E McCoyDivision of Infection and Immunity, University College London, London, UK.
R K GuptaCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
University of Cambridge · GBCambridge University Hospitals NHS Foundation Trust · GBUniversity College London · GBAddenbrooke's Hospital · GBNHS Blood and Transplant · GBAmsterdam UMC Location University of Amsterdam · NLMedway School of Pharmacy · GBMRC Laboratory of Molecular Biology · GBUniversity of Colorado Denver · US

Funding

Modeling evolution of functional context in proteinsR01GM083127 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI POLLOCK, DAVID D · 2009 to 2019
$2.7M
Medical Research Council G0701652NIGMS NIH HHS R01 GM083127Wellcome Trust 206618/Z/17/Z
6 · The paper itself

Abstract

SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics are designed around Wuhan-1 Spike, this raises the theoretical possibility of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. Here we report chronic SARS-CoV-2 with reduced sensitivity to neutralising antibodies in an immune suppressed individual treated with convalescent plasma, generating whole genome ultradeep sequences by both short and long read technologies over 23 time points spanning 101 days. Although little change was observed in the overall viral population structure following two courses of remdesivir over the first 57 days, N501Y in Spike was transiently detected at day 55 and V157L in RdRp emerged. However, following convalescent plasma we observed large, dynamic virus population shifts, with the emergence of a dominant viral strain bearing D796H in S2 and

Indexed as

antibody escapeConvalescent plasmaCOVID-19evasionimmune suppressionmutationneutralising antibodiesresistanceSARS-CoV-2

Identifiers

PMID33398302
PMCPMC7781345
OpenAlexW3111019319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.